Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

681
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
681
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

30
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
30
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

9
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
9

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcatheter Closure of Post-Myocardial Infarction Ventricular Septal Rupture Using an Atrial Septal Defect Occluder.

JACC. Case reports·2026
Same author

Stable, Progressive, and Acute Valve Syndrome in Severe Aortic Stenosis: Insights from the CURRENT AS Registry-2.

Journal of the American Heart Association·2026
Same author

Clinical Outcomes After Drug-Eluting Stent Thrombosis in Patients on Hemodialysis　- Insights From the REAL-ST Registry.

Circulation journal : official journal of the Japanese Circulation Society·2026
Same author

Cardiac damage stages at follow-up and subsequent clinical outcomes in patients with severe aortic stenosis.

Cardiovascular intervention and therapeutics·2026
Same author

A case report of Impella 5.5-induced accordion phenomenon of the right subclavian artery during coronary bypass surgery.

European heart journal. Case reports·2026
Same author

Author's reply.

Journal of cardiology·2026

Related Experiment Video

Updated: Jul 14, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.6K

Statin Discontinuation After Coronary Revascularization.

Ko Yamamoto1, Takeshi Morimoto2, Masahiro Natsuaki3

  • 1Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.

The American Journal of Cardiology
|October 5, 2023
PubMed
Summary

Approximately 1 in 5 patients with coronary artery disease discontinued statin therapy after coronary revascularization. Statin discontinuation, driven by nonadherence or side effects, significantly increased subsequent mortality risk in real-world practice.

Keywords:
coronary artery bypass graftingpercutaneous coronary interventionstatin

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.3K

Related Experiment Videos

Last Updated: Jul 14, 2025

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.6K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.3K
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.3K

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Statin therapy is crucial for managing coronary artery disease (CAD).
  • Real-world data on statin discontinuation in post-coronary revascularization patients are scarce.
  • Understanding reasons for discontinuation is vital for patient outcomes.

Purpose of the Study:

  • To evaluate the incidence and reasons for statin discontinuation in patients after coronary revascularization.
  • To assess the association between statin discontinuation and subsequent mortality.

Main Methods:

  • Analysis of 11,144 patients from the CREDO-Kyoto Registry Cohort-3 who underwent first coronary revascularization and were taking statins.
  • Statin discontinuation defined as cessation for at least two months.
  • Median follow-up of 6 years.

Main Results:

  • Cumulative incidence of statin discontinuation reached 21.4% at 7 years.
  • Major reasons included nonadherence (2.35 HR), side effects (2.48 HR), and worsening comorbidities (22.08 HR).
  • Statin discontinuation strongly associated with increased mortality (3.54 HR).

Conclusions:

  • Real-world statin discontinuation is common after coronary revascularization, affecting nearly one-fifth of patients within 7 years.
  • Nonadherence, side effects, and worsening comorbidities are primary drivers.
  • Discontinuation significantly elevates mortality risk, underscoring the need for adherence support.